ArticleGenes & diseases2019
Evaluation on monoamine neurotransmitters changes in depression rats given with sertraline, meloxicam or/and caffeic acid.
Article in Genes & diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 40 citations in OpenAlex.
- Electrochemically grown Cu,Ni-BTC film for the electrochemical detection of caffeic acid in fruits.RSC advances · 2026Article
- Antidepressant-like effects of Ashwagandha (Withania Somnifera) on chronic unpredictable mild stress-induced depression in adolescent rats.Psychopharmacology · 2026Article
- Relationship between sedentary time and cognitive decline in hypertensive patients-mediating role of the weight-adjusted waist circumference index.Scientific reports · 2025Article
- Metabolite classification through novel metabolomics framework reveals mechanism underlying the therapeutic effects of PSD95-nNOS blockade for post-stroke depression.Metabolomics : Official journal of the Metabolomic Society · 2025Article
- Therapeutic potential of COX-2 inhibitors in neuropsychiatric disorders.Journal of neural transmission (Vienna, Austria : 1996) · 2025Review
- Genistein improves depression-like behavior in rats by regulating intestinal flora and altering glutamate gene expression.Current research in food science · 2025Article
- Neuroplasticity and Mechanisms of Action of Acute and Chronic Treatment with Antidepressants in Preclinical Studies.Biomedicines · 2024Review
- Effect of Shenqi Jieyu formula on inflammatory response pathway in hippocampus of postpartum depression rats.Heliyon · 2024Article
- Article
- Caffeic Acid and Diseases-Mechanisms of Action.International journal of molecular sciences · 2022Review
- Phenolic Acids as Antidepressant Agents.Nutrients · 2022Review
- Biology of cyclooxygenase-2: An application in depression therapeutics.Frontiers in psychiatry · 2022Review
- Genistein acts as antidepressant agent against chronic mild stress-induced depression model of rats through augmentation of brain-derived neurotrophic factor.Brain and behavior · 2021Article
- Neuroprotective Efficiency of Prodigiosins Conjugated with Selenium Nanoparticles in Rats Exposed to Chronic Unpredictable Mild Stress is Mediated Through Antioxidative, Anti-Inflammatory, Anti-Apoptotic, and Neuromodulatory Activities.International journal of nanomedicine · 2021Article
- Rivaroxaban Modulates TLR4/Myd88/NF-Kβ Signaling Pathway in a Dose-Dependent Manner With Suppression of Oxidative Stress and Inflammation in an Experimental Model of Depression.Frontiers in pharmacology · 2021Article
- Optimization of food deprivation and sucrose preference test in SD rat model undergoing chronic unpredictable mild stress.Animal models and experimental medicine · 2020Article
- Associations Among Monoamine Neurotransmitter Pathways, Personality Traits, and Major Depressive Disorder.Frontiers in psychiatry · 2020Review
- Antidepressant Potential of Cinnamic Acids: Mechanisms of Action and Perspectives in Drug Development.Molecules (Basel, Switzerland) · 2019Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammation drives the development of depression and may affect neurotransmitters and thus neurocircuits increase the risk of depression. To investigate the influence of inhibition of inflammatory pathways on the biogenic amine neurotransmitters metabolism in depressive rats, sertraline, and meloxicam, the inhibitors of arachidonic acid - cyclooxygenase-2/lipoxygenase (AA-COX-2/5-LO) pathways, were given to depressive rats. After the development of depression model by chronic unpredictable mild stress (CUMS) for 6 weeks, Successful modeling rats were selected and randomly divided into CUMS group and medication administration group. After given medicine, The biogenic amine neurotransmitters in rat cortex and hippocampus were measured by high-performance liquid chromatography equipped with an electrochemical detector (HPLC-ECD). Compared with the normal group, the concentration of norepinephrine (NE) significantly decreased and the concentrations of Tyrosine (Tyr), Tryptophan (Trp), 3,4-dihydroxyphenyl acetic acid (DOPAC), 3-methoxy-4-hydroxyphenylglycol (MHPG), homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5-HIAA) significantly increased in the CUMS group. Sertraline significantly inhibited the elevation of 5-HIAA. Meloxicam inhibited the decrease of NE level in CUMS-induced rat and the increase of Trp, MHPG, and 5-HIAA level in a dose-dependent manner. Caffeic acid inhibited the decrease of NE and the increase of Trp and MHPG in a dose-dependent manner. The inhibition of AA-COX-2/5-LO pathways can improve the behaviors of depression rats and suppress CUMS-induced changes in biogenic amines. Compared with the single-dose lipoxygenase (5-LO) or Cyclooxygenase-2 (COX-2) inhibitor, the combination treatment with meloxicam 1 mg/kg and caffeic acid 10 mg/kg have no significant improvement in CUMS-induced depression behavior and the level of cortical monoamine neurotransmitters and their metabolites.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.